Allison Beck

发表

The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial

Tianwei Yu, Mark R Prausnitz, Sebastien Henry, 2017, The Lancet.

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

J. Mascola, T. Pierson, C. Andrews, 2017, The Lancet.

Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 Exposure

M. Mulligan, K. Ault, N. Rouphael, 2020, Vaccines.

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old

M. Mulligan, W. Keitel, Shital M. Patel, 2015, The Journal of infectious diseases.

Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus.

Philip Smith, Karen K. Wong, R. Davey, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.

Johannes B. Goll, S. El-Kamary, M. Mulligan, 2017, Vaccine.

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.

J. Mascola, Zonghui Hu, A. McDermott, 2022, The New England journal of medicine.

Phase Ib Trial To Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of Filociclovir (MBX-400, Cyclopropavir) in Healthy Volunteers

M. Mulligan, N. Rouphael, S. Hurwitz, 2019, Antimicrobial Agents and Chemotherapy.

An Oil-in-Water adjuvant significantly increased influenza A/H7N9 split virus Vaccine-Induced circulating follicular helper T (cTFH) cells and antibody responses.

Julia K. Weiss, M. Mulligan, N. Rouphael, 2022, Vaccine.

A High Throughput Whole Blood Assay for Analysis of Multiple Antigen-Specific T Cell Responses in Human Mycobacterium tuberculosis Infection

A. Nizam, L. Waller, J. Altman, 2018, The Journal of Immunology.

Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.

R. Davey, J. Alimonti, G. Kobinger, 2015, JAMA.

Innate, T-, and B-Cell Responses in Acute Human Zika Patients

M. Mulligan, Shital M. Patel, K. Murray, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

J. Mascola, D. Baltimore, E. Boritz, 2022, Nature Medicine.

Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial

D. Bernstein, M. Mulligan, N. Rouphael, 2014, Open forum infectious diseases.

Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.

J. Mascola, T. Pierson, R. Koup, 2020, JAMA.

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults

Carmen M. Graves, J. Mascola, R. Koup, 2023, Science Translational Medicine.

Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.

Johannes B. Goll, S. El-Kamary, M. Mulligan, 2017, Vaccine.